News
Valneva must immediately cease U.S. shipments and sales of Ixchiq, a vaccine for chikungunya virus. The FDA recently lifted a ...
Less than three weeks after lifting a pause on the use of Valneva’s chikungunya vaccine Ixchiq, the FDA has done an ...
Shares of French drugmaker Valneva slumped more than 20% on Monday after the U.S. Food and Drug Administration suspended the ...
The US Food and Drug Administration (FDA) announced late last week that it has suspended the license for French drugmaker ...
The United States Food and Drug Administration (FDA) has suspended the license for Valneva's chikungunya vaccine Ixchiq with ...
The FDA suspends Ixchiq, the only approved chikungunya vaccine, over safety concerns, impacting its availability in the U.S.
Valneva shares fall after FDA suspends Ixchiq vaccine license citing new safety reports, raising questions over future U.S.
Earlier this month, the FDA backed off on a pause in shipments of the chikungunya vaccine Ixchiq to older adults. Now, the ...
US health authorities have suspended the license for the Ixchiq vaccine against the chikungunya virus following reports of ...
Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that the United States Food and Drug Administration (FDA) has suspended the license for IXCHIQ ®, citing ...
Investing.com -- Valneva SE ADR (NASDAQ:VALN) stock tumbled 20.4% premarket Monday after the U.S. Food and Drug ...
The agency said it had become aware of more reports of serious adverse events, leading center director Vinay Prasad to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results